3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Cholangiocarcinoma
6
Carcinoma, Transitional Cell
5
Acrocephalosyndactylia
5
Neoplasm Metastasis
3
Gastrointestinal Neoplasms
3
Breast Neoplasms
3
Recurrence
2
Pancreatic Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Solid Tumor, Miscellaneous
1
Solid Tumor
1
Sarcoma
1
Oligodendroglioma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Myeloproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Locally Advanced Unresectable Gastric Cancer
1
Liposarcoma
1
Hematologic Neoplasms
1
Glioma
1
Glioblastoma
1
Interventions
Cyclophosphamide
41
fludarabine
35
Tacrolimus
28
Mycophenolic Acid
27
Whole-Body Irradiation
25
Busulfan
24
fludarabine phosphate
21
Melphalan
19
thymoglobulin
16
Antilymphocyte Serum
16
Methotrexate
13
Thiotepa
12
Stem Cell Transplantation
9
Rituximab
9
Granulocyte Colony-Stimulating Factor
9
Filgrastim
8
Cyclosporine
8
trametinib
7
Sirolimus
7
Nivolumab
5
ruxolitinib
4
merphos
4
Peripheral Blood Stem Cell Transplantation
4
Cytarabine
4
Cord Blood Stem Cell Transplantation
4
Bendamustine Hydrochloride
4
tocilizumab
3
itacitinib
3
fedratinib
3
dabrafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hematologic Neoplasms
×
pemigatinib
×
Clear all
NCT05159245
2024-07-15
FINPROVE
Helsinki University Central Hospital
Phase 2
Recruiting
250 enrolled